MD102
/ MDBiolab
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 09, 2022
New discovery and development of transglutaminase 2 inhibitor
(AACR 2022)
- "MD102, a TGase2 inhibitor, is expected to be a potential candidate in TGase2-overexpressing cancers, including RCC and TNBC, as it shows antitumor activity without serious toxicity, although further validation is required. In addition, it is expected that area expansion to many diseases induced by TGase2 pathogenesis"
Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • HIF1A • RELA • TGM2
1 to 1
Of
1
Go to page
1